IriSys facility consists of 10,000 SF regulated by Standard Operating Procedures and current Good Manufacturing Practices.  Three cGMP manufacturing suites accommodate lot sizes appropriate for Phase I and Phase II clinical trials.  IriSys maintains a California Drug Manufacturers License.